Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 14/20 | 0.63 |
| ▸ | PAK4 | O96013 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054255 | 0.87 | PLK4 (0.67) | PLK4PAK4NTRK1MEN1HTT | |
| SCHEMBL30373001 | 0.82 | HAVCR2 (0.56) | PLK4AURKAAURKBMEN1KMT2A | |
| SCHEMBL25884471 | 0.81 | PLK4 (0.54) | PLK4PAK4NTRK1GSK3BGSK3A | |
| SCHEMBL173716 | 0.78 | PLK4 (0.58) | PLK4PAK4NTRK1AURKAAURKB | |
| SCHEMBL174456 | 0.78 | PLK4 (0.59) | PLK4PAK4NTRK1AURKAMEN1 | |
| SCHEMBL25882406 | 0.77 | PLK4 (0.51) | PLK4PAK4NTRK1PDE2A | |
| SCHEMBL23889636 | 0.77 | PLK4 (0.57) | PLK4PAK4NTRK1 | |
| SCHEMBL174860 | 0.76 | PLK4 (0.56) | PLK4PAK4NTRK1AURKB | |
| SCHEMBL23889314 | 0.75 | PLK4 (0.75) | PLK4PAK4 | |
| SCHEMBL25875753 | 0.74 | RET (0.46) | PLK4PAK4NTRK1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PLK4 1763/4885PAK4 143/4885NTRK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.